Fiduciary Alliance LLC Has $5.89 Million Stake in Danaher Corporation $DHR

Fiduciary Alliance LLC lowered its stake in shares of Danaher Corporation (NYSE:DHR) by 16.3% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 29,691 shares of the conglomerate’s stock after selling 5,772 shares during the period. Fiduciary Alliance LLC’s holdings in Danaher were worth $5,886,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. White Pine Capital LLC raised its holdings in Danaher by 1.4% in the 2nd quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock valued at $690,000 after acquiring an additional 49 shares in the last quarter. Boyd Watterson Asset Management LLC OH increased its position in shares of Danaher by 2.1% during the second quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after purchasing an additional 51 shares during the period. Worth Financial Advisory Group LLC raised its stake in shares of Danaher by 4.6% in the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after purchasing an additional 53 shares in the last quarter. Bruce G. Allen Investments LLC lifted its position in Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after purchasing an additional 54 shares during the period. Finally, Texas Bank & Trust Co boosted its stake in Danaher by 1.6% during the second quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock worth $705,000 after buying an additional 55 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 3,298 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the sale, the director owned 20,762 shares of the company’s stock, valued at $4,702,593. This represents a 13.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at $552,352.50. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,248 shares of company stock worth $6,609,663 in the last 90 days. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $222.91 on Thursday. The stock has a market capitalization of $157.45 billion, a P/E ratio of 45.96, a price-to-earnings-growth ratio of 4.36 and a beta of 0.89. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The firm has a 50 day moving average of $219.53 and a 200-day moving average of $206.53.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same period last year, the firm posted $1.71 EPS. The business’s revenue was up 4.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s payout ratio is currently 26.39%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DHR. Wells Fargo & Company increased their price objective on shares of Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a research note on Monday. HSBC raised their price target on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. TD Cowen upped their price objective on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. Finally, Redburn Partners set a $220.00 price target on Danaher in a research note on Wednesday, October 8th. Twenty equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and an average price target of $248.25.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.